Fourteen clinical trials in the past 3 years have examined the potential of omega-3 fatty acids in treating psychiatric disorders. Preliminary findings in at least 700 patients suggest that:
- omega-3 fatty acids used as adjuncts or monotherapy appear well-tolerated and safe in psychiatric disorders
- efficacy data vary by disorder
- the two marine omega-3 fatty acids may differ in efficacy.
Although we cannot offer specific guidance for using omega-3 fatty acids at this time, we can update you on recent trials of these “fish oils” in depression, bipolar disorder, schizophrenia, and other psychiatric disorders.
Prevalence rates of major depression1,2 and suicidal ideation3 decrease in populations as fish consumption increases. Some studies4,5 have shown omega-3 fatty acid deficiency in erythrocyte membranes and serum of depressed patients. This putative deficiency has been hypothesized to lead to:
- alterations in membrane fluidity, which affect monoamine (particularly serotonin) neurotransmission6,7
- an imbalance between omega-6 and omega-3 fatty acids, which affects the inflammatory response system (Box).5-12
- Nemets et al. 13 Twenty patients with recurrent major depression taking maintenance antidepressants were randomly assigned to adjunctive ethyl-EPA, 2 grams/d, or placebo for 4 weeks. Patients given ethyl-EPA showed significantly greater improvement than the placebo group in depressive symptoms, as measured by the Hamilton Rating Scale for Depression (HRSD).13
- Peet and Horrobin. 14 Seventy depressed patients taking antidepressants were randomly assigned to adjunctive ethyl-EPA (1, 2, or 4 grams/d) or placebo for 12 weeks. Only the group taking ethyl-EPA, 1 gram/d, showed significantly greater improvement than the placebo group.
- Su et al. 15 Twenty-eight patients taking antidepressants for major depression were randomly assigned to adjunctive omega-3 fatty acids (4.4 grams/d of EPA plus 2.2 grams/d of DHA) or placebo. After 8 weeks, depressive symptoms improved significantly more in the adjunctive treatment group.
- Marangell et al. 16 Thirty-six patients with mild to moderate depression (defined as a score of 17 on the 28-item HRSD) were randomly assigned to monotherapy with DHA, 2 grams/d, or placebo. Response rates after 6 weeks were comparable (27.8% with DHA versus 23.5% with placebo).
Polyunsaturated fatty acids contain a hydrocarbon chain with two or more double bonds. They are divided into families based on the location of their first double bond relative to the methyl end carbon—the “omega” carbon. Polyunsaturated fatty acids of interest in psychiatry include:
- omega-6 fatty acids—arachidonic acid (AA) and linoleic acid (LA)
- omega-3 fatty acids—eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA).
Omega-3 and omega-6 fatty acids are called “essential” because they must be obtained from dietary sources. EPA and DHA are derived largely from wild—not farm-raised—fish, including sea bass, mackerel, pike, sardines, salmon, trout, herring, and cod liver oil.8 ALA, a precursor to both EPA and DHA, is derived from plant sources such as flaxseed oil, canola oil, walnuts, and soybean oil.
Polyunsaturated fatty acids, particularly AA and DHA, are important components of the phospholipid bilayer of neuronal cell membranes.They increase the ability of phospholipids to move “fluidly” within the membrane and modulate neurotransmission6,7 and signal transduction pathways9,10 thought to be important in psychiatric disorders. They also are precursors for eicosanoid molecules (such as prostaglandins and leukotrienes) and cytokines. Thus, an imbalance favoring omega-6 fatty acids over omega-3 fatty acids may lead to overproduction of pro-inflammatory cytokines.11
Omega-3 fatty acids are thought to be beneficial in numerous inflammatory and cardiovascular diseases. The American Heart Association’s dietary guidelines include dietary sources of omega-3 fatty acids as part of a healthy diet.12 Unfortunately, typical Western culture diets disproportionately favor foods rich in cholesterol and omega-6 fatty acids instead.
Controlled trials of omega-3 fatty acids in treating major depression
|Author, year of publication||Duration and dosages||Number of patients||Results|
|Nemets et al, 2002 13||4 weeks, 2 grams/d of ethyl-EPA in recurrent depression||20||Significantly greater reduction in mean HRSD scores in ethyl-EPA group(-12.4) compared with placebo group (-1.6)|
6 of 10 patients in ethyl-EPA group achieved 50% reduction in HRSD scores, compared with 1 in 10 patients in placebo group
|Peet and Horrobin, 2002 14||12 weeks, 1, 2, or 4 grams/d of ethyl-EPA||70||Patients receiving 1 gram/d of ethyl-EPA showed significantly greater reduction in:|
|Su et al, 2003 15||8 weeks, 4.4 grams/d of EPA and 2.2 grams/d of DHA||28||Treatment group showed significantly greater reduction in HRSD scores from baseline at weeks 4, 6, and 8 than placebo group|
|Marangell et al, 2003 16||6 weeks, 2 grams/d of DHA||36||Little difference between response rates in DHA group (27.8%) and placebo group (23.5%)|
|BDI: Beck Depression Inventory|
|DHA: docosahexaenoic acid|
|EPA: eicosapentaenoic acid|
|HRSD: Hamilton Rating Scale for Depression|
|MADRS: Montgomery-Åsberg Depression Rating Scale|